To investigate the role of integrin ␣7 in muscle pathology, we used a "candidate gene" approach in a large cohort of muscular dystrophy/myopathy patients. Antibodies against the intracellular domain of the integrin ␣7A and ␣7B were used to stain muscle biopsies from 210 patients with muscular dystrophy/ myopathy of unknown etiology. Levels of ␣7A and ␣7B integrin were found to be decreased in 35 of 210 patients (ϳ17%). In six of these patients no integrin ␣7B was detected. Screening for ␣7B mutation in 30 of 35 patients detected only one integrin ␣7 missense mutation (the mutation on the second allele was not found) in a patient presenting with a congenital muscular dystrophy-like phenotype. No integrin ␣7 gene mutations were identified in all of the other patients showing integrin ␣7 deficiency. In the process of mutation analysis, we identified a novel integrin ␣7 isoform presenting 72-bp deletion. This isoform results from a partial deletion of exon 21 due to the use of a cryptic splice site generated by a G to A missense mutation at nucleotide position 2644 in integrin ␣7 cDNA. This spliced isoform is present in about 12% of the chromosomes studied. We conclude that secondary integrin ␣7 deficiency is rather common in muscular dystrophy/myopathy of unknown etiology, emphasizing the multiple mechanisms that may modulate integrin function and stability. Integrins are transmembrane heterodimers of two different subunits, ␣ and ␤, associated by non-covalent interactions. In humans, at least 18 different ␣ and 8 different ␤ subunits are known, resulting in 22 distinct heterodimers.
Integrins are transmembrane heterodimers of two different subunits, ␣ and ␤, associated by non-covalent interactions. In humans, at least 18 different ␣ and 8 different ␤ subunits are known, resulting in 22 distinct heterodimers.
1,2 The ␣7 subunit is mainly expressed in skeletal and cardiac muscle, while the ␤1 chain is expressed throughout the body and associated with other different ␣ subunits. [3] [4] [5] [6] In adults, the alternative ␤1D isoform is restricted to skeletal and cardiac muscle. [7] [8] [9] Integrin ␣7␤1 in skeletal and cardiac muscle binds via its extracellular domain to laminin ␣2 and ␣4 10 -12 and via its cytoplasmic domain possibly to ␣-actinin and talin ensuring continuity of structure and signaling between the cytoskeleton and the basal lamina. 13, 14 Integrins have a prominent role in myogenesis, 15, 16 differentiation, cell migration, and cell-cell interactions. 2, [17] [18] [19] Integrin ␣7 in skeletal muscle localizes at the sarcolemma, at the neuromuscular junctions, and, most prominently, at the myotendinous junctions where it provides an anchorage for laminin ␣2, conferring mechanical stability and traction resistance to the skeletal muscle fibers. 5, 9, 20, 21 The expression of several integrin ␣7 isoforms modulates the integrin ␣7␤1 ligand affinity and signaling specificity during myogenesis. 20 All integrin isoforms are encoded by a single ␣7 gene (ITGA7) located on chromosome 12q13 22 and result from alternatively spliced variants. 20, 23 In humans, different extracellular and cytoplasmic domain isoforms have been described. 23, 24 The ␣7X1 and ␣7X2 extracellular isoforms result from the alternative splicing of exons 5 or 6, in a variable region nearby the ligand binding site. 5, 24, 25 The X2 isoform is the main variant expressed in adult muscle fibers. 24, 26 The cytoplasmic isoform ␣7A, 20, 24, 27 corresponding to the normal exon 26 splicing, is temporarily up-regulated during myogenesis, while the ␣7B variant, the longest isoform resulting from the splicing out of exon 26, is the main isoform expressed in skeletal and cardiac muscle, smooth muscle cells, spleen, liver, and brain. 20, 28 To study the involvement of ␣7 integrin during myogenesis and its role in muscle integrity and function, a null allele of the gene for the ␣7 integrin subunit has been generated. 29 Mice homozygous for the mutation showed features of a progressive muscular dystrophy in their muscle, suggesting that integrin ␣7 represents an indispensable linkage between the muscle fiber and the ex-tracellular matrix, 29 particularly at the myotendinous junction. To further support the role of integrin in connecting muscle cells with the surrounding extracellular matrix, it has been shown that ␣7␤1 is up-regulated in Duchenne muscular dystrophy (DMD) patients and in its animal model, mdx mice, to compensate for the reduced dystrophin-mediated linkage of fibers with the basal lamina. 11, 30 In merosin-negative congenital muscular dystrophy (CMD) and in its animal model, dy/dy mice, ␣7 integrin appears to be significantly reduced suggesting that lack of laminin ␣2 (␣2␤1␥1) may down-regulate the expression or change the location of integrin ␣7 gene. 11, 12, 30 The cloning of the full-length human ITGA7 cDNA 5, 26, 31 allowed the identification of the first three patients with primary ␣7 integrin deficiency. 31 The three patients reported were affected with congenital myopathy with variable clinical phenotype, and all showed a complete absence of integrin ␣7 in their muscle biopsies due to primary integrin ␣7 nonsense/splicing mutations or to a down-regulation of integrin ␣7 mRNA. 31 Here we report a study of a large series of muscle biopsies from patients affected with unclassified muscular dystrophy/ myopathy tested for integrin ␣7 deficiency by combined integrin ␣7 protein and gene studies.
Materials and Methods

Patients
Our muscle biopsy tissue bank at the Neuromuscular Center of the University of Padova was screened to search for patients meeting the following criteria: muscle weakness and/or hypotonia; muscle histopathology consistent with a myopathic or dystrophic process; and normal dystrophin, ␣-sarcoglycan, calpain, dysferlin, and laminin ␣2 in their muscle biopsies. Inflammatory myopathies, neurogenic atrophies, and metabolic or mitochondrial myopathies were a priori excluded. Two hundred ten patients met the clinical and histopathological selection criteria and were chosen for integrin ␣7 screening. One hundred thirteen were muscular dystrophies, 24 CMD, and 73 carried a histopathological diagnosis of undetermined myopathy.
Case Report
Patient E.S. was delivered by Caesarian section at the 39th gestational week due to the threat of miscarriage. The child was oxygen-dependent and mechanically ventilated since birth. He presented with hypotonia and with hip, wrist, and ankle contractures. Karyotype study was normal. A brain computed tomography (CT) scan showed cortical atrophy and white matter signal abnormalities. Creatine kinase (CK) was 507 U/L (normal Ͻ250) and electromyography (EMG) myopathic. At one month of age a muscle biopsy was consistent with a congenital muscular dystrophy. Dystrophin, ␣-sarcoglycan, and laminin ␣2 studies in his muscle biopsy were normal. The patient died at 13 months of age from respiratory failure. Integrin ␣7 was markedly reduced in the patient's muscle biopsy.
Integrin ␣7 Immunohistochemistry
Serial cryosections, 4-m thick, were fixed for 5 minutes in 100% ice-cold-acetone, air dried, and preincubated with phosphate-buffered saline containing 2% bovine serum albumin and 5% goat serum as blocking agent. 31 Polyclonal anti-integrin ␣7B antibody (1:500) directed against the intracellular domain of the protein, 12 polyclonal anti-integrin ␣7A antibody (1:500) directed against the COOH terminal peptide of the protein, polyclonal anti-␤1D (1:500), 12 and monoclonal antibody directed against the carboxyl terminus region of the laminin ␣2 (1:1000) 32 (Chemicon, Temecula, CA) were used to incubate the sections for 2 hours at room temperature. Appropriate Cy-3-conjugated (anti-rabbit or anti-mouse) secondary antibody (1:100) (Caltag Lab, Burlingame, CA) were used. The visualization of mounted sections was done on Zeiss Axioskop photomicroscope. Hematoxylin and eosin staining was done on parallel cryosections to check tissue integrity and histopathology.
Muscle biopsies were scored as integrin ␣7B negative, integrin ␣7B markedly reduced, or integrin ␣7B slightly reduced (based on the amount of integrin ␣7 immunostaining detected in each muscle biopsy). The same criteria were used to score ␣7A immunostaining.
Integrin ␣7␤ Mutation Studies
RNA extraction
Approximately 50 mg of frozen muscle biopsy tissue was homogenized using a Kinematica Polytron PT 2100 homogenizer. RNA was extracted using Trizol (Invitrogen, Carlsbad, CA) accordingly to the manufacturer's instructions and stored in RNase-free water at Ϫ80°C.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
For cDNA synthesis, ϳ1-2 micrograms of RNA was reverse transcribed using oligo-dT primers as previously described. 33 cDNA was boiled to denature and inactivate reverse transcriptase. Eighteen sets of overlapping primers were designed to cover the entire 3414 bp of the integrin ␣7 coding sequence and the 5[prime]-UTR region (Table 1) . PCR reactions contained about 50 ng of cDNA, 50 ng of each primer, 100 nmol/L of each dNTP, and 0.2 Ci ␣-[
32 P] dATP in 12.5 l total volume. Reaction conditions were 10 minutes at 94°C to denature; 30 seconds at 94°C, 30 seconds at 65°C, 30 seconds at 72°C for 35 cycles, with an extension of 10 minutes at 72°C for all primer sets except primer sets 1212F-1451R and 2068F-2245R where the annealing temperature was 50°C.
Single Strand Conformational Polymorphism Analysis
Three different single strand conformational polymorphism (SSCP) conditions 33 were used for screening for integrin ␣7 mutation. Conformers were re-amplified using the original amplification primer and PCR conditions as previously described 33 and directly sequenced on automatic sequencer (CRIBI Biotechnology Center, Department of Biology, University of Padova).
The integrin ␣7 mutations identified were confirmed with the appropriate restriction endonuclease digestion if a gain or loss of restriction site was detected or with appropriate PCR primers designed to cover the mutated region and PCR product size-fractioned with denaturing polyacrylamide gel electrophoresis. Primers used to amplify exon 15 and exon 21 were as following: ex 15F 5Ј-TGC-CCCTTATCTATGTCTCC-3Ј;ex15R5Ј-GAGAGGGCTTTCT-CTCAATCC-3Ј; ex 21F 5Ј-TCCCCTCATACTCTCTTTTTCC-3Ј, and ex 21R 5Ј-AACTCCCCATAACATCTGTAACC-3Ј.
Integrin ␣7 Gene Expression Studies
RNA extraction and cDNA synthesis were done as described above. Biopsies studied were from the 30 patients screened for integrin ␣7 mutation and from 10 integrin ␣7-positive myopathic control muscle biopsies.
Primer sets for co-amplification of integrin ␣7 RNA and ␣-sarcoglycan RNA were designed, and for each set the forward primer was synthesized with fluorescein-linked 5Ј ends (Invitrogen). Primer sequences were as follows: ␣-sarcoglycan ADH3F: 5Јfluorescein-CTGCT-CAACGTCACCTCTG-3Ј; ADH3R: 5Ј-CCGGCACTGACT-TATCCAC-3Ј; and integrin ␣7 ITGA7.9F: 5Јfluorescein-TTGATGGTGATGGGAAAGTCTTCA-3Ј; and ITGA7.12R: 5Ј-CAGACCCTTAGGTCCACACAGACC-3Ј.
Multiplex RT-PCR and quantitation of fluorescent PCR products were done as previously described. 34 Briefly, cDNA corresponding to approximately 20 ng of total RNA was amplified with primers mixed for 22 cycles using standard conditions (denaturation at 95°C for 10 minutes, at 94°C for 1 minute, at 62°C for 1 minute, at 72°C for 1 minute, for 22 cycles; and extension at 72°C for 10 minutes). Fluorescent RT-PCR products were denatured and loaded on an ABI automated sequencer (Applied Biosystems, Foster City, CA) using a ROX/fluorescein matrix standard. ROX labeled markers were included as internal size standards. Peak areas corresponding to expected RT-PCR product sizes were determined, and peak area ratios of integrin ␣7 relative to internal control (␣-sarcoglycan) calculated. Two separate RT-PCR measurements were done for each patient's biopsy. Statistical significance was done by Student's t test using all calculated ratios.
Results
Histological Features of 35 Integrin ␣7-Deficient Patients
The entire database, about 5000 muscle biopsies, was searched for patients meeting the histopathological diagnosis of muscular dystrophy of unknown etiology (normal dystrophin, ␣-sarcoglycan, calpain, dysferlin, and laminin ␣2). About 560 muscle biopsies, collected over 2 consecutive years, were searched for undetermined myopathy. Two hundred ten patients were selected for integrin ␣7 screening from the database search of muscle biopsies. One hundred thirty seven muscular dystrophy and 73 myopathies were tested with integrin ␣7 immunofluorescence. Muscle biopsies from patients diagnosed with muscular dystrophy showed marked fiber size variation, increased central nuclei, degeneration and regeneration, and a marked increase in the endomysial and perimysial connective tissue with fatty infiltration. Common features in the undetermined myopathy group of muscle biopsies included mild fiber size variation and scattered central nuclei, with little or absent muscle fiber degeneration or regeneration. Fibrofatty infiltration was absent or minimal.
Antibodies directed against the ␣7A, ␣7B, and the ␤1D subunit of integrin were used to characterize integrin expression in patients' muscle biopsies. In parallel, lami- 56F, 5Ј-TTGGGGCGTGCGAGATTTC-3Ј  249R, 5Ј-CTGCCCAGGAAGAGCCAGGGC-3Ј  32F, 5Ј-GGGCCTCCGGGATTTGCTAC-3Ј  279R, 5Ј-AGCGAAGAGGCCTCCAGTGC-3Ј  201F, 5Ј-GAGCTGGCTGCTGGTGGGTGC-3Ј  467R, 5Ј-GTCTCCAGGATCTGGTCCAC-3Ј  410F, 5Ј-TTGTTACCTGTGCACACCGAT-3Ј  676R, 5Ј-GCAACCCCTTCCAATTATAGG-3Ј  608F, 5Ј-CCGCCTTCTCCCCTGATAG-3Ј  841R, 5Ј-AGCTCAGCTCTTCTGCACG-3Ј  807F, 5Ј-GGGGAAAGGTCTGGTGCG-3Ј  1022R, 5Ј-GCACCCACTATCAGGTCTGGCC-3Ј  980F, 5Ј-TGACCTCAACAGTGATGGCTG-3Ј  1282R, 5Ј-CCTGTGAAGGTTTGGCGAC-3Ј  1212F, 5Ј-CTTTGATGGTGATGGGAAAGTC-3Ј  1451R, 5Ј-GCAATAGAGACCTCATGGGAG-3Ј  1391F, 5Ј-ACACCGCAGTGCTCTTCAGGGC-3Ј  1648R, 5Ј-GGTTACGGCTCAGGAACGTC-3Ј  1581F, 5Ј-GTTAGATGCGGACACAGACCG-3Ј 1894R
nin ␣2 immunostaining was done in each muscle biopsy to check the integrity of the muscle fibers. Three percent (6 of 210) of the muscle biopsies studied were completely deficient for integrin ␣7B (Table 2 ; Figure 1G ) and about 14% (29 of 210) showed a (variable) reduction of integrin ␣7B immunostaining (Table 2 ; Figure 1 , M and Q). Six muscle biopsies showing complete integrin ␣7B deficiency were all undetermined muscular dystrophy ( Figure 1G ). Three were diagnosed as CMD and 3 as limb-girdle muscular dystrophy. Marked integrin ␣7B reduction (ie, variable and barely detectable integrin ␣7 immunostaining in the majority of the muscle fibers with or without some scattered myofibers showing patchy but positive immunostaining) ( Figure 1M ) was present in about 6% (8 of 137) of the muscular dystrophies and in 15% (11 of 73) of the myopathies studied ( Table 2) . A slight reduction in integrin ␣7B (ie, variable and faint integrin ␣7 immunostaining and/or a mosaic-like pattern) ( Figure 1Q ) was detected in 5% (7 of 137) of muscular dystrophies and in about 4% (3 of 73) of unclassified myopathy (Table 2) . Interestingly, the integrin ␣7-positive muscle fibers, in the subset of ␣7B partial deficiency, often showed a integrin ␣7-positive cytoplasmic immunostaining. Integrin ␣7A was reduced ( Figure 1 , H, N, R), and integrin ␤1D mildly reduced ( Figure 1 , F, L, P) in all muscle biopsies showing integrin ␣7B deficiency. In the six muscle biopsies showing complete integrin ␣7B deficiency, integrin ␣7A was more severely decreased than in the partial deficiency. Laminin ␣2 was normal in all biopsies studied (Figure 1 , E, I, O). Integrin ␣7B deficiency was present in about 39% (11 of 28) ( Table 2 ) of muscle biopsies from patients younger than 2 years, and only in 13% (24 of 182) ( Table 2 ) from patients older than 2 years. To determine whether integrin ␣7B deficiency in younger patients was a manifestation of integrin ␣7B being expressed at a lower level at a younger age, we selected a patient with a marked reduction of integrin ␣7B in muscle at 1 year of age who had two subsequent muscle biopsies obtained at 2 and 6.3 years of age. Integrin ␣7B immunostaining was performed in parallel with laminin ␣2 and integrin ␤1D in the three-muscle biopsy. As shown in Figure 2 , the patient's muscle biopsy performed at 2 years of age ( Figure 2C ) contained scattered myofibers with a faint and variable integrin ␣7B immunostaining. Rare fibers showed a patchy and barely detectable integrin ␣7B immunostaining in the muscle biopsy performed at 6.3 years of age ( Figure 2F ). Integrin ␤1D was mildly reduced (Figure 2 , B and E), and laminin ␣2 was normal in these biopsies ( Figure 2, A and D) .
Integrin ␣7 Mutation Studies
Adequate muscle tissue for RNA extraction was available for 30 of 35 muscle biopsies showing integrin ␣7B deficiency. Twenty were muscular dystrophies (including the six samples showing complete ␣7B deficiency) and 10 were myopathies. These 30 muscle biopsies were selected for integrin ␣7 mutation screening. RNA was extracted and RT-PCR/SSCP was performed using 18 sets of overlapping primers covering the entire integrin ␣7 coding sequence.
Integrin ␣7 Polymorphisms
Several conformers were identified and directly sequenced. Seven integrin ␣7 polymorphisms were identified. All of the identified polymorphisms were in the extracellular domain of the protein. Of the seven polymorphisms identified, six were silent nucleotide changes: G285T (Pro95Pro), G351A (Glu117Glu), A366G (Gln122Gln), G810A (Gly270Gly), T2307C (Ser769Ser), and C3018G (Ser1006Ser). An A1952G nucleotide change resulted in a histidine to an arginine amino acid change (His651Arg). The A1952G nucleotide change was present in 32 of 70 (46%) of the chromosomes studied.
Integrin ␣7 Alternatively Spliced Isoform
A unique conformer was detected with primer set 2607F-2868R in a single patient. Sequencing showed an inframe deletion mutation starting at nucleotide position 2641 to nucleotide position 2712 of the integrin ␣7 coding sequence (Figure 3 ). The heterozygous in-frame deletion encompassed 72 bp in exon 21. This in-frame deletion detected at the cDNA level was absent at the genomic DNA level suggesting that the recognition of a cryptic splice site within exon 21 may be responsible for the skipping of about 40% of exon 21 directly to exon 22. To further characterize this in-frame deletion we performed SSCP on exon 21 in genomic DNA from the patient and Figure 2 . Integrin ␣7 deficiency in a two-year-old patient is not rescued over time. Cryosections from muscle biopsies performed at 2 years (A-C), and 6.3 years of age (D-F) in the same patient were stained with an antibody directed against the intracellular domain of the integrin ␣7B (C and F), integrin ␤1D (B and E), and laminin ␣2 (A and D) . In C (a muscle biopsy performed at 2 years of age), integrin ␣7B is faintly expressed in a minority of the patient's muscle fibers. In the muscle biopsy performed at 6.3 years of age the number of integrin ␣7-positive fibers is dramatically reduced and strongly integrin ␣7-positive fibers are no longer detectable (F). Integrin ␤1D was mildly reduced in both of the patient's muscle biopsies (B and E) and laminin ␣2 was normal (A and D). from 60 controls. Identical conformers were detected in the patient and in 14 of 120 chromosomes studied (ϳ12%). Sequence analysis of the conformers showed a G to A substitution at position 2644 in cDNA (Figure 3) . The G2644A base change resulted in a glutamic acid to lysine amino acid change (E822K) and it caused a gain of MseI restriction digestion site. Appropriate restriction digestion and RFLP analysis confirmed the mutation in the genomic DNA of the patient.
Interestingly, when the G2644A mutated exon 21 sequence was searched for a splice site using a Splice Site Finder program (supported by Genet.sickkids.on.ca) a cryptic donor splice site sequence was identified (AG/ GTTA 2644 AG) (Figure 4) . When the score of the cryptic donor sequence was calculated using an algorithm based on the matrix compiled by Shapiro and Senapathy, 35 the cryptic donor splice site AG/GTTA 2644 AG) scored 71.0 where the wild-type donor sequence (TG 2712 /GTGAGG) obtained 84.3 (accordingly to a Splice Site Score Calculator program supported by Genet. sickkids.on.ca).
Integrin ␣7 Mutation
One of the 30 patients studied showed a heterozygous integrin ␣7 mutation. Patient E.S. showed a unique conformer with primer set 1850F-2083R (Figure 4 ). Direct sequencing of the aberrant conformers showed an heterozygous C to G nucleotide change at position 1969 in this patient ( Figure 5 ). The C1969G nucleotide change resulted in a arginine to glycine amino acid change at position 657 of the integrin ␣7 protein. The Arg657Gly is located in the region containing the major ADP-ribosylation site. The C1969G nucleotide change resulted in a loss of a SmaI restriction-enzyme site. To verify the frequency of this mutation in the control population, integrin ␣7 exon 15 was PCR-amplified, and the PCR products were digested with SmaI. Digestion fragments were present in all of 200 control chromosomes but only in one allele of the patient's DNA (heterozygous mutation) (Figure 5, bottom) .
Integrin ␣7B Gene Expression Studies
The same 30 patients used for integrin ␣7 mutation studies were selected for RNA studies. Ten muscle biopsies with myopathic histopathology but with normal integrin ␣7B immunofluorescence were chosen as controls. 5 . Screening of the integrin ␣7 coding sequence for potential mutations by SSCP showed a C1969G heterozygous nucleotide change resulting in an Arg657Gly amino acid change in patient E.S. Top: SSCP analysis of RT-PCR product for primer set 1850F-2083R showed a unique conformer in patient E.S. (The second conformer detected resulted in a A1952G nucleotide change (His651Arg). This polymorphism was present in 46% of the chromosomes studied). Direct sequencing of the aberrant conformer showed a C to G nucleotide change at position 1969 of the integrin ␣7 coding sequence (middle) resulting in an arginine to glycine amino acid change at position 657 of the integrin ␣7 protein. Nucleotide change C1969G resulted in a loss of SmaI restriction-enzyme site. Primers were designed to amplify exon 15 of the integrin ␣7 gene and the PCR product was digested with SmaI. Digestion fragments were present in 200 control chromosomes and only in one of the patient's chromosomes (heterozygous mutation) (bottom).
RNA was isolated from patients' muscle biopsies and 100 ng of total RNA was reverse transcribed into cDNA using oligo dT 10 primers. Approximately 20 ng of total cDNA was amplified using both integrin ␣7 and ␣-sarcoglycan primers. Quantitative multiplex fluorescent RT-PCR (QMF-RT/PCR) products (22 cycles) were done in duplicate for each sample and electrophoresed on an ABI automatic sequencer (373A) to quantitate signals using peak area. Integrin ␣7 versus ␣-sarcoglycan RNA ratios were determined. The patients' muscle biopsies showed a normal amount of total integrin ␣7 RNA relative to controls in their muscles ( Figure 6 ). Mean integrin ␣7 versus ␣-sarcoglycan ratios were 24.2 Ϯ 10 in the controls and 24.3 Ϯ 11 in the patients' group. Student's t-test did not show any significant difference between patients' and controls' integrin ␣7 RNA levels (P ϭ 0.8).
Discussion
Despite the recent advances in our understanding of the molecular basis of neuromuscular disorders, the underlying molecular defect can be identified only in a subset of the cases. A large cohort of patients with muscular dystrophy/myopathy cannot be assigned a specific molecular diagnosis. The goal of this study was to pursue an integrin ␣7 candidate protein and gene analysis in our large cohort of muscular dystrophy/myopathy patients of unknown etiology. This approach was chosen since candidate protein and gene studies have shown impressive progress in dissecting the heterogeneous limb-girdle dystrophy group. To date, dystrophies caused by ␣-, ␤-, and ␦-sarcoglycan have all been defined via candidate gene and protein approaches. 36 -40 The cloning of the integrin ␣7 gene, 31 the preferential expression of integrin ␣7 in skeletal muscle, [41] [42] [43] and the identification of causative integrin ␣7 mutations in a subset of Japanese patients presenting with congenital myopathy 31 made integrin ␣7 an ideal candidate gene for screening a large bank of patient muscle biopsies. Candidate protein and gene analyses were conducted by using integrin ␣7 immunofluorescence in 210 muscle biopsies of patients affected with muscular dystrophy or myopathy of unknown etiology and followed by direct mutation screening of muscle biopsy RNA in 30 patients in which integrin ␣7 deficiency was identified. No integrin ␣7 mutations were identified in 29 of 30 patients showing various degrees of integrin ␣7 deficiency ranging from complete to slight deficiency. Only in one patient presenting at birth with CMD and showing, by immunofluorescence, a marked reduction of integrin ␣7 in his muscle biopsy, an heterozygous C1969G missense mutation resulting in an arginine to a glycine amino acid change (Arg657Gly) was identified. Despite our efforts, we were unable to identify in this patient a second mutation, consistent with the presumed recessive inheritance observed in CMD. We feel that the C1969G nucleotide change may be a causative mutation based on several lines of evidence. First, the C1969G results in an arginine to a glycine amino acid change (Arg657Gly). Arginine is a large, charged amino acid with a molecular weight of 174, whereas glycine is a small, (molecular weight 75) uncharged, polar amino acid. It is unlikely that such a dramatic amino acid change would have no functional consequences in an heterodimeric protein. Second, the C1969G mutation was not observed in 200 control chromosomes and it is located in a region of documented functional importance. The Arg657Gly mutation lies in the region containing the major ADP-ribosylation site 44 that it is likely involved in the mechanisms modulating ␣7 integrin-mediated signaling pathways.
Several integrin ␣7 polymorphisms were also identified. In particular, we report a novel alternatively spliced integrin ␣7 isoform, generated from the use of a cryptic splice site in exon 21 (AG/GTTA 2644 AG), that was derived from a G2644A nucleotide change. The use of this cryptic splice site resulted in the skipping of about 40% of exon 21 directly to exon 22. This splice variant is present in about 12% of the chromosomes studied. A Senpathy score of at least 70 is required for donor splice site recognition. 45 The AG/GTTA 2644 AG cryptic donor site sequence scored only 71, thus the splicing theory would predict that the AG/GTTA 2644 AG sequence would be a weak donor site. Since both normal and cryptic mRNA are observed, both splice sites are used. However, the ratio between the normal and cryptic RNA favors the normal transcript (Figure 3) , suggesting that the utilization of the cryptic AG/GTTA 2644 AG splice is incomplete. It is difficult to predict the functional importance of this alternatively spliced integrin ␣7 isoform that removes 27 amino acids at a region where a major ADP-ribosylation site and a potential integrin leucyl-aspartyl-valine (LDV) binding site have been located. 26 While it is possible that the spliced variant may act as a modifying factor in a predisposing genetic background, it is also possible that it is without any functional and/or structural importance. Among the several integrin ␣7 isoforms previously reported, 5, 20, [23] [24] [25] [26] [27] [28] the ␣7D, resulting from a partial deletion of exon 15 and the entire exon 16, is particularly interesting encompassing the major ADP-ribosylation site. 23, 26 Unfortunately, the exact role of ADP-ribosylation on ␣7 integrins remains to be determined, 26 thus the potential functions of these isoforms are still largely unknown.
It has been reported that the expression of the cytoplasmic splice variant ␣7B is developmentally regulated, and that it is detectable in skeletal muscle only after the age of 2 years. 30 Since we used an antibody against the integrin ␣7B variant, we checked if the integrin ␣7 deficiency was related to the age of the patients at the time of the biopsy. Indeed, 39% (11 of 28) of the muscle biopsies of patients younger than 2 years compared to 13% (24 of 182) of patients older than 2 years showed integrin ␣7 deficiency. Even if this difference is significant, we feel that factors other than developmental stage may affect the sarcolemmal expression of the ␣7B integrin subunit in diseased skeletal muscle, as suggested by Cohn et al. 30 In the only patient where consecutive muscle biopsies were available, the integrin ␣7 deficiency detected in the muscle biopsy performed at 1 year of age was not rescued in the subsequent muscle biopsies done at 2 and 6.3 years of age. Moreover, 60% (17 of 28) of patients younger than 2 years showed normal integrin ␣7 immunostaining. The positive integrin ␣7 immunostaining detected in patients younger than 2 years of age may also be interpreted as some yet undefined compensatory mechanisms acting in dystrophic/myopathic muscle as suggested by the expression of integrin ␣7B in DMD and in the hypertrophic muscle fibers in SMA (spinal muscular atrophy) patients younger than 2 years. 30 To better investigate the discrepancy between the integrin ␣7 protein deficiency detected through immunofluorescence analysis of patients' muscle biopsies and the lack of identification of integrin ␣7 gene mutations, we conducted a series of experiments.
Our inability to detect integrin ␣7 gene mutation in integrin ␣7-deficient muscle samples is not likely due to technical reasons. We cannot rule out that mutations in the promotor region or in some intronic sequences that we did not analyze, underlie the observed integrin ␣7 deficiency. However, we feel that our mutation detection system is quite sensitive (we calculated about 93% sensitivity in a previous study). 46 Since laminin ␣2 deficiency, both partial or total, is a well-known cause of secondary integrin ␣7 deficiency, 11, 12, 30 all of the 210 muscle biopsies included in this study were checked by laminin ␣2 immunofluorescence, and all were normal.
To determine whether the decreased accumulation of integrin ␣7 protein might be the result of protein instability or due to the lack of integrin ␣7 gene expression or RNA processing, we quantitated total RNA from muscle biopsies of integrin ␣7-deficient patients. QMF-RT/PCR has been shown to have a relatively low experimental error, and has the additional advantage of using internal control RNA for each test. 47 Our results showed normal integrin ␣7 mRNA levels in the patients studied suggesting that the loss of integrin ␣7 in their muscle biopsies occurs at the protein level. It is possible that the observed secondary integrin ␣7 deficiency may be the result of an incorrect processing and/or location of a normally synthesized integrin ␣7 protein in the patients' muscles. The cytoplasmic integrin ␣7-positive immunostaining observed in some of our patients' muscle biopsies further support the hypothesis of a integrin ␣7 moiety that is properly produced but is mislocated or unstable at the membrane level in absence, for example, of some yet unknown ligand. Quantitation of integrin ␣7, such as by immunoblotting analysis, may be informative, but unfortunately the small size of our diagnostic biopsies is a limiting factor. The biopsies are not sufficient to obtain a membrane-enriched pellet, and this limitation did not allow us to perform such an analysis in this study.
Taken together, our results suggest that secondary integrin ␣7 deficiency is rather common in muscular dystrophy/myopathy of unknown etiology. This is not surprising considering the central role played by ␣7␤1D integrin in anchoring the intracellular cytoskeleton via actin, to the extracellular matrix, via laminin, and the potential for signal transduction possibly mediated by extracellular matrix, soluble growth factors, and/or associated transmembrane molecules. "Inside-out" and "inside-in" signals can mutually modulate the activation of cell proliferation and migration, and if this signaling is malfunctioning, the lack of appropriate cell matrix interaction can lead to cell death via apoptosis. 48 Analyses of mutant phenotypes provide further evidence of the key role of integrins in adhesion-mediated events in vertebrates. Germ-line mutations in genes coding for other laminin binding integrin result in disease. For example, mutations in either the ␣6 or the ␤4 subunit of the epithelial hemidesmosomes integrin result in a variant of the usually lethal skin blistering disorder, epidermolysis bullosa. ␣3 integrin in epithelia plays a direct role in the assembly of the basement membrane as shown by the ␣3-null mice that show basement membrane abnormalities in the kidney, lung, and skin and die soon after birth. 48 Further work is necessary to obtain more insight into the role of integrin-mediated adhesion and signaling and their modulating factors.
